LAVA Therapeutics N.V. (LVTX)

NASDAQ: LVTX · IEX Real-Time Price · USD

2.740

0.00 (0.00%)

At close: Apr 24, 2024, 12:00 AM

2.750

+0.010 (0.36%)

After-hours: Apr 24, 2024, 7:22 PM EDT

LAVA Therapeutics Income Statement

Financials in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019
Revenue	6.77	19.39	5.35	3.75	0
Revenue Growth (YoY)	-65.09%	262.45%	42.78%	-	-
Cost of Revenue	3.48	0	0	0	0
Gross Profit	3.29	19.39	5.35	3.75	0
Selling, General & Admin	12.73	14.12	12.02	2.72	1.24
Research & Development	33.81	40.11	36.95	15.7	8.35
Operating Expenses	46.54	54.23	48.96	18.42	9.58
Operating Income	-43.25	-34.84	-43.61	-14.67	-9.58
Interest Expense / Income	-2.97	-0.26	0.63	0.34	0.09
Other Expense / Income	1.41	-2.92	-2.04	0.87	0.02
Pretax Income	-41.7	-31.66	-42.2	-15.88	-9.69
Income Tax	0.28	0.25	0.16	0.04	0
Net Income	-41.97	-31.91	-42.36	-15.93	-9.69
Shares Outstanding (Basic)	27	26	20	0	0
Shares Outstanding (Diluted)	27	26	20	0	0
Shares Change	3.12%	31.21%	4850.36%	-10.81%	-
EPS (Basic)	-1.57	-1.23	-2.14	-39.91	-21.65
EPS (Diluted)	-1.57	-1.23	-2.14	-39.91	-21.65
Free Cash Flow	-39.7	3.46	-29.41	-9.81	-9.38
Free Cash Flow Per Share	-1.49	0.13	-1.49	-24.58	-20.95
Gross Margin	48.56%	100.00%	100.00%	100.00%	-
Operating Margin	-638.99%	-179.66%	-815.20%	-391.59%	-
Profit Margin	-620.09%	-164.55%	-791.68%	-425.06%	-
Free Cash Flow Margin	-586.53%	17.82%	-549.74%	-261.78%	-
EBITDA	-43.39	-31.13	-41.02	-15.08	-9.34
EBITDA Margin	-640.97%	-160.56%	-766.64%	-402.40%	-
Depreciation & Amortization	1.28	0.78	0.56	0.46	0.26
EBIT	-44.67	-31.92	-41.57	-15.54	-9.6
EBIT Margin	-659.85%	-164.59%	-777.07%	-414.79%	-

Source: Financials are provided by Nasdaq Data Link and sourced from audited reports submitted to the Securities and Exchange Commission (SEC).